Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates - ViDoe

Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates

189 views

Celerion - Clinical Research

11 months ago

Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates

Drug Labeling Studies in Clinical Pharmacology: Recent FDA/EMA Updates

$Drug Labeling Studies in Clinical Pharmacology: Recent FDA\/EMA Updates$

57:35

Drug Labeling Studies in Clinical Pharmacology: Recent FDA\/EMA Updates

by Celerion - Clinical Research

Drug Transporters in ADME and Drug Action with Dr. Joseph Ware

42:20

Drug Transporters in ADME and Drug Action with Dr. Joseph Ware

by NIH Clinical Center

$PBPK Modeling \& Simulation to Support asciminib NDA Submission and Inform Drug Product Label$

1:01:14

PBPK Modeling \& Simulation to Support asciminib NDA Submission and Inform Drug Product Label

Webinar — Patient Centricity and the Evolving Role of Microsampling

1:02:17

Webinar — Patient Centricity and the Evolving Role of Microsampling

by Altasciences

Regulatory Services: Navigating Clinical Trial applications

1:35

Regulatory Services: Navigating Clinical Trial applications

by Innomar Strategies

FDA and Health Canada Regional ICH Consultation Part II

1:03:29

FDA and Health Canada Regional ICH Consultation Part II

by U.S. Food and Drug Administration

LIFE SCIENCES | DAILY NEWS | AUGUST 21, 2024 | PHARMASHOTS

1:00

LIFE SCIENCES | DAILY NEWS | AUGUST 21, 2024 | PHARMASHOTS

Pharmac Panel | Paula Bennett, Todd Stephenson and Dr David Hughes

1:10:20

Pharmac Panel | Paula Bennett, Todd Stephenson and Dr David Hughes

by Leukaemia \& Blood Cancer New Zealand

Nutraceuticals 4 2024

44:30

Nutraceuticals 4 2024

by Pick Pharma DXP

Dyne Therapeutics (July) - Meet the DM Drug Developers 2024

1:13:33

Dyne Therapeutics (July) - Meet the DM Drug Developers 2024

by Myotonic Dystrophy Foundation

$Patient Reported Outcomes as endpoints in oncology trials and marketing claims: FDA\/EMA perspective$

59:44

Patient Reported Outcomes as endpoints in oncology trials and marketing claims: FDA\/EMA perspective

by Mapi Research Trust

Pharma Functional Areas Deep Dive Series Pt 1 - Regulatory

42:28

Pharma Functional Areas Deep Dive Series Pt 1 - Regulatory

by PILs Connect

Backing up clinical data with modelling | Marco Siccardi, PhD

13:08

Backing up clinical data with modelling | Marco Siccardi, PhD

by Academic Medical Education

Clinical Pharmacology Issues That Can Lead to Approvability Problems for Your Drug

58:10

Clinical Pharmacology Issues That Can Lead to Approvability Problems for Your Drug

Refelctions on the Role of PHarmacogenomic Biomarkers in Drug Labels - Lawrence Lesko, Ph.D., F.C.P.

51:11

Refelctions on the Role of PHarmacogenomic Biomarkers in Drug Labels - Lawrence Lesko, Ph.D., F.C.P.

Rare Disease Endpoint Advancement RDEA Pilot Program

11:08

Rare Disease Endpoint Advancement RDEA Pilot Program

by Critical Path Institute

Pharmacometrics in Phase 3 – Data Integration and Analysis to Support Dose and Labeling for the NDA

20:56

Pharmacometrics in Phase 3 – Data Integration and Analysis to Support Dose and Labeling for the NDA

by Simulations Plus, Inc.

FDA EMA immunogenicity guidelines APR2020

46:41

FDA EMA immunogenicity guidelines APR2020

by maria-dolores vazquez-abad

Lung Cancer Treatment Webinar 2024 Full Recording

1:18:35

Lung Cancer Treatment Webinar 2024 Full Recording

by Academic Medical Education

Baricitinib (OLUMIANT®): Evidence-Based Health Information Related to COVID-19

38:05

Baricitinib (OLUMIANT®): Evidence-Based Health Information Related to COVID-19

by The Society of Infectious Diseases Pharmacists